Actively Recruiting
Immune Response to Pneumosil Versus Typhoid Conjugate Vaccine in Children 6-59 Months Hospitalized with Severe Acute Malnutrition A Randomized Controlled Trial
Led by Nick Fancourt · Updated on 2026-10-08
214
Participants Needed
1
Research Sites
48 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the immune response generated by a pneumococcal conjugate vaccine Pneumosil compared to a Typhoid conjugate vaccine Typbar TCV in young children aged 6 to 59 months who are hospitalized with severe acute malnutrition. This phase 4, double-blind, randomized controlled trial aims to see if Pneumosil produces a better immune response to pneumococcal serotypes when measured 28 days after vaccination. Participants are randomly assigned to receive either a single dose of Pneumosil or Typbar TCV once they are medically stable during the transition phase of malnutrition care. At 3 months after the initial vaccination, those who received Pneumosil will get a dose of Typbar TCV, and those who initially received Typbar TCV will get Pneumosil, ensuring all children receive both vaccines. The study involves 264 children and includes follow-up visits at their homes. During the six months following vaccination, participants will have four home visits and a phone review at 12 months after vaccination. Researchers will collect blood and saliva samples to measure immune responses, monitor recovery from malnutrition, check for pneumococcal carriage, re-hospitalization, and mortality. The primary outcome is the level of serotype-specific immunoglobulin G antibodies measured four weeks after vaccination, with ongoing safety and health assessments throughout the study duration.
CONDITIONS
Brief Title
Opportunistic Pneumococcal Immunisation Trial in MALnutrition
Research Team
N
Nicholas S. S. Fancourt, PhD
J
Jane N Nelson, Bachelor of Nursing
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here